 Bleomycin
"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 2 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 3 | 5 | | 2012 | 3 | 3 | 6 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 4 | 4 | | 2015 | 1 | 2 | 3 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 5 | 6 | | 2018 | 5 | 6 | 11 | | 2019 | 2 | 8 | 10 | | 2020 | 2 | 7 | 9 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 3 | 4 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Bousamaki J, Rørbeck EA, Petersen AG, Korntner SH, Pors SE, Redente EF, Oró D, Salinas CG, Olsen RW, Simonsen U, Feigh M, Hansen HH. Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis. Physiol Rep. 2025 Sep; 13(18):e70560.
-
Brazee P, Allen N, Knipe R, Redente EF, Le Saux CJ. Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions. Semin Respir Crit Care Med. 2025 Aug; 46(4):330-346.
-
Hernández-Benítez J, López-Azcarraga A, Flerlage JE, Castellino S, Aristizabal P, Hoppe BS, Milgrom SA, de Paula MJA, Mailhot Vega RB. Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations. JCO Glob Oncol. 2025 Jun; 11:e2400485.
-
King EM, Zhao Y, Moore CM, Steinhart B, Anderson KC, Vestal B, Moore PK, McManus SA, Evans CM, Mould KJ, Redente EF, McCubbrey AL, Janssen WJ. Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung. JCI Insight. 2024 Dec 20; 9(24).
-
Muraoka S, Brodie WD, Mattichak MN, Gurrea-Rubio M, Ikari Y, Foster C, Amin MA, Khanna N, Amin H, Campbell PL, Vichaikul S, Model EN, Omara MM, Petrovski S, Kozicki K, Amarista C, Webber A, Ali M, Palisoc PJ, Hervoso J, Ruth JH, Tsoi LC, Varga J, Gudjonsson JE, Khanna D, Fox DA, Tsou PS. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis Rheumatol. 2025 Jan; 77(1):80-91.
-
Burgy O, Mayr CH, Schenesse D, Fousekis Papakonstantinou E, Ballester B, Sengupta A, She Y, Hu Q, Melo-Narvaéz MC, Jain E, Pestoni JC, Mozurak M, Estrada-Bernal A, Onwuka U, Coughlan C, Parimon T, Chen P, Heimerl T, Bange G, Schmeck BT, Lindner M, Hilgendorff A, Ruppert C, Güenther A, Mann M, Yildirim AÖ, Eickelberg O, Jung AL, Schiller HB, Lehmann M, Burgstaller G, Königshoff M. Fibroblast-derived extracellular vesicles contain SFRP1 and mediate pulmonary fibrosis. JCI Insight. 2024 Aug 15; 9(18).
-
Zimmermann R, Roeder F, Ruppert C, Smith BJ, Knudsen L. Low-volume ventilation of preinjured lungs degrades lung function via stress concentration and progressive alveolar collapse. Am J Physiol Lung Cell Mol Physiol. 2024 Jul 01; 327(1):L19-L39.
-
Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023 12 26; 7(24):7485-7493.
-
Dobrinskikh E, Hennessy CE, Kurche JS, Kim E, Estrella AM, Cardwell J, Yang IV, Schwartz DA. Epithelial Endoplasmic Reticulum Stress Enhances the Risk of Muc5b-associated Lung Fibrosis. Am J Respir Cell Mol Biol. 2023 01; 68(1):62-74.
-
Ahangari F, Becker C, Foster DG, Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead B, Meador C, Correll K, Lili LN, Roybal HM, Rose KA, Ding S, Barnthaler T, Briones N, DeIuliis G, Schupp JC, Li Q, Omote N, Aschner Y, Sharma L, Kopf KW, Magnusson B, Hicks R, Backmark A, Dela Cruz CS, Rosas I, Cousens LP, Dudley JT, Kaminski N, Downey GP. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 12 15; 206(12):1463-1479.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|